Menu
Investors
OPTIMIZED BY EVOLUTION
Wugen is developing off-the-shelf cellular therapies for cancer
Our cell therapy products originate from healthy donors and are optimized to enhance their anti-tumor function.
- Abingworth Bioventures
- Aisling Capital
- Alexandria Venture Investments
- BioGenerator
- Falcon Edge Capital
- Fidelity Management & Research Company, LLC
- Intermediate Capital Group (ICG)
- Lightchain Capital
- LYZZ Capital
- RiverVest Ventures
- Sands Capital
- Tybourne Capital Management
- Velosity Capital Management
Next in our story
Copyright © 2021 Wugen. All Rights Reserved.
a COGNEO design